eligibility_summary
Eligible: 18–80 yrs with histologically proven supratentorial glioblastoma expressing CA12 after standard surgery+radio/chemo, with no/stable residue ≤5 cm3 ≥6 wks post-RT, KPS ≥60, resection cavity 2.5–25 cm3, contraception/negative pregnancy test, adequate marrow, liver (incl Gilbert), clotting, renal (eGFR ≥60). Exclude: imaging contraindications, intraventricular cavity/CSF leak, other active cancer, breastfeeding, serious comorbidity/infection, recent trial (<6 wks), allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05533242 tests Lu-177–labeled 6A10 Fab (LuCaFab), a radiolabeled monoclonal antibody Fab fragment for intracavitary radioimmunotherapy after standard GBM therapy. Drug type/mechanism: 6A10 Fab specifically binds and inhibits carbonic anhydrase XII (CA XII) on glioma cells, the attached lutetium-177 emits short-range β-particles to deliver localized radiation and induce DNA damage. Intracavitary, fractionated dosing (3 cycles, 4-week intervals) bypasses the blood–brain barrier and concentrates dose to the 2 cm margin of the resection cavity while limiting systemic exposure. Targets: CA XII–positive glioblastoma cells near the cavity, CA XII is a hypoxia-inducible membrane enzyme that regulates extracellular acidification/pH homeostasis, supporting tumor invasion and therapy resistance. Primary aims: MTD, safety, and organ/tissue dosimetry, exploratory efficacy via 24-week PFS.